Click on the protein name for more information about the protein.
The Score column is the predicted score of interaction between the two proteins
Click on the Evidence link to view a breakdown of the information about the predicted interaction.
| Key | |
|---|---|
| Module Score | Databases |
![]() | Where interaction is observed in another database a link is provided: |
| Protein 1 (?) | Protein 2 (?) | Name of Protein 2 | Module Scores (?) | Scores (?) | Evidence (?) | Database (?) | |||
|---|---|---|---|---|---|---|---|---|---|
![]() | ![]() | ![]() | ![]() | ||||||
| FOS | JUNB | JUNB: Transcription factor jun-B | 5.36E3 | Evidence |
O
|
||||
| FOS | JUN | JUN: Transcription factor AP-1 | 2.51E3 | Evidence |
O
|
||||
| FOS | MAFB | MAFB, KRML: Transcription factor MafB | 201.0 | Evidence | |||||
| FOS | DUSP1 | DUSP1, CL100, MKP1, PTPN10, VH1: Dual specificity protein phosphatase 1 | 114.0 | Evidence | |||||
| FOS | ETS2 | ETS2: Protein C-ets-2 | 70.20 | Evidence | |||||
| FOS | FOSL2 | FOSL2, FRA2: Fos-related antigen 2 | 62.90 | Evidence | |||||
| FOS | RXRA | RXRA, NR2B1: Retinoic acid receptor RXR-alpha | 59.5 | Evidence | |||||
| FOS | ATF1 | ATF1: Cyclic AMP-dependent transcription factor ATF-1 | 51.50 | Evidence | |||||
| FOS | CREBBP | CREBBP, CBP: CREB-binding protein | 51.50 | Evidence | |||||
| FOS | RB1 | RB1: Retinoblastoma-associated protein | 43.60 | Evidence |
O
|
||||
| FOS | BATF | BATF: Basic leucine zipper transcriptional factor ATF-like | 43.60 | Evidence |
O
|
||||
| FOS | NFE2L2 | NFE2L2, NRF2: Nuclear factor erythroid 2-related factor 2 | 39.10 | Evidence | |||||
| FOS | MAPK9 | MAPK9, JNK2, PRKM9: Mitogen-activated protein kinase 9 | 37.80 | Evidence | |||||
| FOS | NR3C1 | NR3C1, GRL: Glucocorticoid receptor | 35.40 | Evidence | |||||
| FOS | GTF2F2 | N/A | 34.80 | Evidence |
O
|
||||
| FOS | MYB | MYB: Myb proto-oncogene protein | 34.80 | Evidence | |||||
| FOS | NFKBIA | NFKBIA, IKBA, MAD3, NFKBI: NF-kappa-B inhibitor alpha | 32.90 | Evidence | |||||
| FOS | VDR | VDR, NR1I1: Vitamin D3 receptor | 31.70 | Evidence | |||||
| FOS | MAPK3 | MAPK3, ERK1, PRKM3: Mitogen-activated protein kinase 3 | 31.20 | Evidence | |||||
| FOS | BRCA1 | BRCA1, RNF53: Breast cancer type 1 susceptibility protein | 28.20 | Evidence | |||||
| FOS | FOSB | FOSB, G0S3: Protein fosB | 28.2 | Evidence | |||||
| FOS | MAP2K6 | MAP2K6, MEK6, MKK6, PRKMK6: Dual specificity mitogen-activated protein kinase ki | 26.90 | Evidence | |||||
| FOS | SMAD2 | SMAD2, MADH2, MADR2: Mothers against decapentaplegic homolog 2 | 26.00 | Evidence | |||||
| FOS | ETS1 | ETS1, EWSR2: Protein C-ets-1 | 25.3 | Evidence |
|
||||
| FOS | MAPK8 | MAPK8, JNK1, PRKM8: Mitogen-activated protein kinase 8 | 24.90 | Evidence | |||||
| FOS | MAPK10 | MAPK10, JNK3, JNK3A, PRKM10: Mitogen-activated protein kinase 10 | 24.90 | Evidence | |||||
| FOS | DDIT3 | DDIT3, CHOP, GADD153: DNA damage-inducible transcript 3 | 22.40 | Evidence |
O
|
||||
| FOS | EGR1 | EGR1, ZNF225: Early growth response protein 1 | 19.90 | Evidence | |||||
| FOS | SMAD4 | SMAD4, DPC4, MADH4: Mothers against decapentaplegic homolog 4 | 19.70 | Evidence | |||||
| FOS | CSNK2A1 | CSNK2A1: CSNK2A1 protein | 19.70 | Evidence |
|
||||
| FOS | SMAD3 | SMAD3, MADH3: Mothers against decapentaplegic homolog 3 | 19.70 | Evidence |
|
||||
| FOS | RELA | RELA, NFKB3: Transcription factor p65 | 19.70 | Evidence |
|
||||
| FOS | GTF2B | GTF2B, TF2B, TFIIB: Transcription initiation factor IIB | 19.70 | Evidence | |||||
| FOS | TCF20 | TCF20, KIAA0292, SPBP: Transcription factor 20 | 19.10 | Evidence | |||||
| FOS | ZNF295 | ZNF295, KIAA1227, ZBTB21: Zinc finger protein 295 | 19.10 | Evidence | |||||
| FOS | DMXL2 | DMXL2, KIAA0856: DmX-like protein 2 | 17.80 | Evidence | |||||
| FOS | SOX8 | SOX8: Transcription factor SOX-8 | 17.10 | Evidence | |||||
| FOS | STAT1 | STAT1: Signal transducer and activator of transcription 1-alpha/beta | 17.10 | Evidence |
|
||||
| FOS | ATAD2 | ATAD2, L16, PRO2000: ATPase family AAA domain-containing protein 2 | 16.40 | Evidence | |||||
| FOS | HIF1A | HIF1A, MOP1: Hypoxia-inducible factor 1 alpha | 16.30 | Evidence | |||||
| FOS | NFIL3 | NFIL3, E4BP4, IL3BP1: Nuclear factor interleukin-3-regulated protein | 15.30 | Evidence | |||||
| FOS | HCK | N/A | 15.10 | Evidence | |||||
| FOS | EP300 | N/A | 14.40 | Evidence | |||||
| FOS | BARD1 | BARD1: BRCA1-associated RING domain protein 1 | 14.20 | Evidence | |||||
| FOS | RIPK1 | RIPK1, RIP: Receptor-interacting serine/threonine-protein kinase 1 | 13.80 | Evidence | |||||
| FOS | NR5A1 | NR5A1, AD4BP, FTZF1, SF1: Steroidogenic factor 1 | 12.70 | Evidence | |||||
| FOS | GRK1 | GRK1, RHOK: Rhodopsin kinase precursor | 12.50 | Evidence | |||||
| FOS | PGR | PGR, NR3C3: Progesterone receptor | 12.50 | Evidence | |||||
| FOS | STAT4 | STAT4: Signal transducer and activator of transcription 4 | 12.50 | Evidence | |||||
| FOS | ZBTB7A | ZBTB7A, FBI1, LRF, ZBTB7: Zinc finger and BTB domain-containing protein 7A | 12.40 | Evidence | |||||
| FOS | SP1 | SP1, TSFP1: Transcription factor Sp1 | 12.30 | Evidence | |||||
| FOS | HMGA1 | HMGA1, HMGIY: High mobility group protein HMG-I/HMG-Y | 11.90 | Evidence | |||||
| FOS | STAT5B | STAT5B: Signal transducer and activator of transcription 5B | 11.90 | Evidence | |||||
| FOS | ATF3 | ATF3: Cyclic AMP-dependent transcription factor ATF-3 | 11.30 | Evidence | |||||
| FOS | SPI1 | SPI1: Transcription factor PU.1 | 11.30 | Evidence | |||||
| FOS | ESR1 | ESR1, ESR, NR3A1: Estrogen receptor | 11.30 | Evidence | |||||
| FOS | STAT3 | 11.20 | Evidence | ||||||
| FOS | ZBTB16 | ZBTB16, PLZF, ZNF145: Zinc finger and BTB domain-containing protein 16 | 11.20 | Evidence | |||||
| FOS | PRKCA | PRKCA, PKCA, PRKACA: Protein kinase C alpha type | 11.20 | Evidence | |||||
| FOS | REST | REST, NRSF, XBR: RE1-silencing transcription factor | 11.00 | Evidence | |||||
| FOS | ZFPM1 | ZFPM1, FOG1: Zinc finger protein ZFPM1 | 10.70 | Evidence | |||||
| FOS | NACA | NACA, HSD48: Nascent polypeptide-associated complex subunit alpha | 10.60 | Evidence | |||||
| FOS | BCL6 | BCL6, BCL5, LAZ3, ZBTB27, ZNF51: B-cell lymphoma 6 protein | 10.10 | Evidence | |||||
| FOS | SMCX | JARID1C, DXS1272E, SMCX, XE169: Histone demethylase JARID1C | 10.10 | Evidence | |||||
| FOS | SMARCA5 | SMARCA5, SNF2H, WCRF135: SWI/SNF-related matrix-associated actin-dependent regul | 9.88 | Evidence | |||||
| FOS | ARFGAP1 | N/A | 9.73 | Evidence | |||||
| FOS | NCOA3 | N/A | 9.73 | Evidence | |||||
| FOS | DDX21 | DDX21: Nucleolar RNA helicase 2 | 9.73 | Evidence | |||||
| FOS | SSRP1 | SSRP1, FACT80: FACT complex subunit SSRP1 | 9.55 | Evidence | |||||
| FOS | STAT5A | STAT5A, STAT5: Signal transducer and activator of transcription 5A | 9.29 | Evidence | |||||
| FOS | RNF31 | ISGF3G, IRF9: Transcriptional regulator ISGF3 subunit gamma | 9.29 | Evidence | |||||
| FOS | JAK2 | JAK2: Tyrosine-protein kinase JAK2 | 9.17 | Evidence | |||||
| FOS | SMAD1 | SMAD1, BSP1, MADH1, MADR1: Mothers against decapentaplegic homolog 1 | 8.92 | Evidence | |||||
| FOS | RUNX1 | N/A | 8.72 | Evidence |
|
||||
| FOS | HDAC3 | HDAC3: Histone deacetylase 3 | 8.72 | Evidence | |||||
| FOS | TDG | TDG: G/T mismatch-specific thymine DNA glycosylase | 8.72 | Evidence | O | ||||
| FOS | ZFP161 | N/A | 8.32 | Evidence | |||||
| FOS | MYBBP1A | MYBBP1A, P160: Myb-binding protein 1A | 7.39 | Evidence | |||||
| FOS | RAF1 | RAF1, RAF: RAF proto-oncogene serine/threonine-protein kinase | 7.38 | Evidence | |||||
| FOS | KHDRBS1 | KHDRBS1, SAM68: KH domain-containing, RNA-binding, signal transduction-associate | 6.62 | Evidence | |||||
| FOS | SCYL3 | SCYL3, PACE1: Protein-associating with the carboxyl-terminal domain of ezrin | 6.48 | Evidence | |||||
| FOS | MAPKAPK5 | N/A | 6.40 | Evidence | |||||
| FOS | AR | AR, DHTR, NR3C4: Androgen receptor | 6.40 | Evidence | |||||
| FOS | DSP | DSP: Desmoplakin | 6.40 | Evidence | |||||
| FOS | JDP2 | jdp2, JDP2: Jun dimerization protein 2 | 6.40 | Evidence | |||||
| FOS | SYTL4 | Endocrine transmitter regulatory protein | 6.40 | Evidence | |||||
| FOS | EIF4G1 | EIF4G1, EIF4F, EIF4G, EIF4GI: Eukaryotic translation initiation factor 4 gamma 1 | 5.89 | Evidence | |||||
| FOS | HNRPM | HNRPM, NAGR1: Heterogeneous nuclear ribonucleoprotein M | 5.73 | Evidence | |||||
| FOS | PRKCB1 | N/A | 5.73 | Evidence | |||||
| FOS | NFYA | NFYA: Nuclear transcription factor Y subunit alpha | 5.73 | Evidence | |||||
| FOS | CAMK2A | N/A | 5.73 | Evidence | |||||
| FOS | SETD3 | SETD3, C14orf154: SET domain-containing protein 3 | 5.73 | Evidence | |||||
| FOS | GRK6 | N/A | 5.73 | Evidence | |||||
| FOS | MSN | MSN: Moesin | 5.45 | Evidence | |||||
| FOS | TCEB3 | TCEB3, MSTP059: Transcription elongation factor B polypeptide 3 | 5.28 | Evidence | |||||
| FOS | IEF-SSP-9502 | PWP1: Periodic tryptophan protein 1 homolog | 5.28 | Evidence | |||||
| FOS | PRKD1 | PRKD1, PKD, PKD1, PRKCM: Serine/threonine-protein kinase D1 | 4.86 | Evidence | |||||
| FOS | NKX2-5 | NKX2-5, CSX, NKX2.5, NKX2E: Homeobox protein Nkx-2.5 | 4.47 | Evidence | |||||
| FOS | FOSL1 | FOSL1, FRA1: Fos-related antigen 1 | 4.08 | Evidence | |||||
| FOS | MYCN | MYCN, NMYC: N-myc proto-oncogene protein | 3.93 | Evidence | |||||
| FOS | MAP3K10 | MAP3K10, MLK2, MST: Mitogen-activated protein kinase kinase kinase 10 | 3.82 | Evidence | |||||
| FOS | SLC9A3R1 | SLC9A3R1, NHERF: Ezrin-radixin-moesin-binding phosphoprotein 50 | 3.78 | Evidence | |||||
| FOS | MAF | MAF: Transcription factor Maf | 3.6 | Evidence |
|
||||
| FOS | DUSP6 | DUSP6, MKP3, PYST1: Dual specificity protein phosphatase 6 | 3.47 | Evidence | |||||
| FOS | HDAC2 | HDAC2: Histone deacetylase 2 | 3.20 | Evidence | |||||
| FOS | JUND | JUND: Transcription factor jun-D | 3.15 | Evidence |
O
|
||||
| FOS | HHEX | HHEX, HEX, PRH, PRHX: Homeobox protein PRH | 3.11 | Evidence | |||||
| FOS | PCSK9 | PCSK9, NARC1, PSEC0052: Proprotein convertase subtilisin/kexin type 9 precursor | 3.07 | Evidence | |||||
| FOS | DUSP16 | DUSP16, KIAA1700, MKP7: Dual specificity protein phosphatase 16 | 2.99 | Evidence | |||||
| FOS | SALL1 | SALL1, SAL1: Sal-like protein 1 | 2.80 | Evidence | |||||
| FOS | HDAC1 | HDAC1, RPD3L1: Histone deacetylase 1 | 2.63 | Evidence | |||||
| FOS | KIAA0683 | DKFZp434A073, DKFZp434I062, KIAA0683, TELO2, hCG_42688: Putative uncharacterized | 2.63 | Evidence | |||||
| FOS | C13orf8 | N/A | 2.54 | Evidence | |||||
| FOS | STK39 | STK39, SPAK: STE20/SPS1-related proline-alanine-rich protein kinase | 2.14 | Evidence | |||||
| FOS | POLR2A | POLR2A: Uncharacterized protein POLR2A | 2.10 | Evidence | |||||
| FOS | AIP | AIP, XAP2: AH receptor-interacting protein | 2.10 | Evidence | |||||
| FOS | DAPK2 | DAPK2: Death-associated protein kinase 2 | 1.9 | Evidence | |||||
| FOS | HUWE1 | HUWE1, KIAA0312, HSPC272, KIAA1578, UREB1: E3 ubiquitin-protein ligase HUWE1 | 1.9 | Evidence | |||||
| FOS | CALM2 | CALM1, CALM, CALM2, CAM2, CALM3, CALML2, CAM, CAMB, CAM3, CAM1, CAMC, CAMIII: Ca | 1.41 | Evidence | |||||